enGene appoints Ryan Daws as CFO and Head of Business Development; new CMO agreement with Richard Bryce

enGene Therapeutics Inc.

Ryan Daws appointed CFO and Head of Business Development, effective Nov 27, 2023; replaces Alexandre Grassin.
Daws receives $440K base salary, 40% bonus, $143.5K signing bonus, and 232,000 stock options vesting over 4 years.
CMO Richard Bryce enters employment agreement with $450K base, 40% bonus, eligibility for 153,000 stock options in 2024.
Bryce's agreement provides severance: 12 months base salary plus benefits upon termination or change in control.
enGene's lead program EG-70 in pivotal study for BCG-unresponsive NMIBC; interim data read-out expected mid-2024.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ryan Daws

Chief Financial Officer and Head of Business Development

ENGN · enGene Therapeutics Inc.

Effective: 2023-11-27
Filed: November 29, 2023, 6:59 PM ET

On November 27, 2023, Ryan Daws became Chief Financial Officer (“CFO”) and Head of Business Development of enGene Holdings Inc.

Departed

Alexandre Grassin

principal financial officer and principal accounting officer

ENGN · enGene Therapeutics Inc.

Effective: 2023-11-27
Successor: Ryan Daws
Filed: November 29, 2023, 6:59 PM ET

Mr. Daws replaced Alexandre Grassin as the Company’s principal financial officer and principal accounting officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ryan Daws was appointed as Chief Financial Officer and Head of Business Development at enGene Therapeutics Inc..

Action: appointed
Role: Chief Financial Officer and Head of Business Development

Exact text from the filing

On November 27, 2023, Ryan Daws became Chief Financial Officer (“CFO”) and Head of Business Development of enGene Holdings Inc.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.8

Alexandre Grassin departed as principal financial officer and principal accounting officer at enGene Therapeutics Inc..

Action: replaced
Role: principal financial officer and principal accounting officer

Exact text from the filing

Mr. Daws replaced Alexandre Grassin as the Company’s principal financial officer and principal accounting officer.

View on SEC.gov

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000929638-23-003305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.